Materialise (MTLS) Q4 2025: Medical Segment Hits 53% of Revenue as Manufacturing Headwinds Persist
Materialise’s Q4 revealed a decisive shift toward its medical segment, now comprising over half of total revenue, as manufacturing softness and software transition dynamics shaped the quarter’s operational story. The company’s dual listing and new €30 million buyback program signal capital allocation flexibility, while ongoing cost discipline and a focus on high-value verticals offset industrial market headwinds. Looking ahead, medical and software investments are prioritized, with manufacturing expected to remain challenged by macro conditions through 2026.
Summary
- Medical Segment Dominance: Medical now drives over half of revenue, reshaping Materialise’s business mix.
- Manufacturing Transition: Persistent industrial softness weighs on prototyping, but aerospace and defense contracts offer future upside.
- Strategic Capital Moves: Dual listing and buyback program expand financial flexibility and investor reach.
Performance Analysis
Materialise delivered Q4 revenue growth of nearly 7% year-over-year, with consolidated revenue reaching €70.2 million. The standout was the medical segment, which grew 16% and set a new quarterly record, now accounting for 53% of total revenue. Software and manufacturing segments were essentially flat or slightly down, reflecting both the ongoing transition to a subscription-based model in software and persistent macro headwinds in manufacturing, especially in prototyping.
Profitability metrics improved meaningfully, with adjusted EBITDA more than doubling to €9.5 million and adjusted EBIT swinging positive, driven by higher gross margins and disciplined cost control. The company’s free cash flow generation strengthened the net cash position to €70.8 million, while deferred revenue from software maintenance and licenses continued to build, supporting future visibility. Manufacturing remained a drag on margins, with negative adjusted EBITDA, but strategic contracts in aerospace and defense were secured for future contribution.
- Medical Outperformance: Segment’s robust growth and margin expansion offsetting weakness elsewhere.
- Software Recurrence: Recurring revenue now 82% of software total, up from 74%, reflecting progress in business model shift.
- Manufacturing Margin Pressure: Ongoing prototyping decline and macro drag keep segment in loss territory despite strategic wins.
Full-year results were flat on revenue but showed operational leverage from cost discipline. Capital allocation shifted with the launch of a €30 million buyback and completion of a dual listing, providing more options for shareholder returns and strategic flexibility.
Executive Commentary
"In the fourth quarter, we surpassed the historical milestone of 700,000 patients treated with Materialise personalized solutions. More than 70,000 patients have been treated in 2025 alone. This represents a significant milestone in our journey towards mass personalization."
Brigitte DeVette, Chief Executive Officer
"Our consolidated adjusted EBITDA reached €9.5 million, more than double the €4.3 million recorded in the same period of last year, with an adjusted EBITDA margin now of 13.6%. These improvements were driven by higher revenue, an increased gross margin percentage, and lower operating expenses when adjusted for non-recurring costs."
Kun Belgias, Chief Financial Officer
Strategic Positioning
1. Medical Segment as Core Growth Engine
The medical business, now 53% of Q4 revenue, is the primary growth driver. Materialise’s push for mass personalization—customized solutions for individual patients—has reached 700,000 cumulative treatments. The launch of new Mimics Flow software brings AI-driven workflow automation, subscription pricing, and improved licensing, aligning company success with customer outcomes and supporting recurring revenue streams.
2. Software Platform Transformation
The software segment is pivoting toward a cloud-based, subscription-first model, with recurring revenue now comprising 82% of the total. Innovations like COEM Bricks, a low-code automation platform, are designed to reduce manual work and speed additive manufacturing workflows. This shift is intended to stabilize and grow the segment, though non-recurring revenue remains in decline during the transition.
3. Manufacturing Refocus and Margin Challenge
Manufacturing continues to face macro headwinds, especially in prototyping, but Materialise is redirecting efforts toward high-value verticals such as aerospace and defense. Strategic wins—like the SONRISA aviation project and Airbus Eurodrone contract—are expected to contribute meaningfully in future periods, though the segment remains a margin drag in the near term.
4. Capital Allocation and Market Access
The dual listing on Euronext Brussels alongside Nasdaq, plus the €30 million share buyback, broadens investor access and provides operational flexibility. No new shares were issued, and the buyback is funded from existing cash, signaling confidence in the company’s financial position and future prospects.
5. Operational Efficiency and Cost Discipline
Disciplined cost management and targeted reductions across segments enabled margin expansion despite flat topline. R&D investments are concentrated in medical and software, while manufacturing and overhead remain under strict cost optimization scrutiny.
Key Considerations
This quarter underscores the company’s structural pivot toward medical and software, leveraging recurring revenue and high-value verticals to offset cyclical manufacturing exposure. The operational and capital allocation moves provide both resilience and optionality as market conditions evolve.
Key Considerations:
- Business Mix Evolution: Medical’s rise to 53% of revenue signals a lasting shift in Materialise’s operating model and growth priorities.
- Software Recurring Revenue: Subscription and maintenance contracts now dominate software revenue, improving visibility and predictability.
- Manufacturing Exposure: Prototyping remains a material but declining portion of manufacturing, with headwinds expected to persist through 2026.
- Capital Flexibility: Dual listing and buyback program provide levers for shareholder return and strategic maneuvering.
- Margin Expansion: Cost controls and segment focus are delivering improved EBITDA and EBIT margins despite flat revenue.
Risks
Materialise faces continued macroeconomic pressure in its manufacturing segment, particularly from a weak industrial climate in Europe that is unlikely to abate near term. The transition to cloud and subscription models in software could create temporary revenue and margin volatility. Execution risk remains around scaling strategic verticals and maintaining cost discipline as the business pivots further toward medical and software. Currency fluctuations, especially a weaker US dollar, also remain a persistent risk to reported results.
Forward Outlook
For Q1 2026, Materialise expects:
- Medical to continue double-digit growth, maintaining segment momentum.
- Manufacturing to remain flat or down, reflecting ongoing industrial softness.
For full-year 2026, management guided to:
- Revenue of €273–283 million, implying low single-digit growth.
- Adjusted EBIT of €10–12 million, reflecting ongoing margin improvement efforts.
Management emphasized continued investment in medical and software, disciplined cost control in manufacturing, and a cautious outlook for industrial demand. Key factors highlighted:
- Strategic contracts in aerospace and defense will begin to contribute, but full impact will take time.
- Software transition to be completed in 2026, further boosting recurring revenue share.
Takeaways
Materialise’s Q4 confirms a decisive pivot to medical and software, with manufacturing remaining a drag due to macro headwinds. Capital allocation flexibility and operational discipline provide resilience, but the company’s long-term trajectory hinges on successfully scaling high-value verticals and completing the software transition.
- Medical and Software Drive Future Value: These segments are positioned for sustainable growth and margin expansion, supported by recurring revenue and innovation.
- Manufacturing Headwinds Remain: Near-term softness will persist, with gradual improvement as strategic contracts ramp up in later periods.
- Watch for Execution on Strategic Verticals: Investor focus should remain on the pace of adoption in aerospace, defense, and recurring software, as well as continued cost discipline and capital allocation moves.
Conclusion
Materialise’s Q4 2025 results mark a clear realignment toward medical and software, with disciplined execution and capital flexibility offsetting manufacturing challenges. The company’s ability to grow high-value segments and deliver on its software transition will be pivotal to sustaining margin expansion and shareholder value in 2026 and beyond.
Industry Read-Through
Materialise’s experience highlights a broader trend in additive manufacturing: the shift from prototyping to production in high-value sectors like medical, aerospace, and defense. Recurring revenue models and workflow automation are becoming critical for software providers, while manufacturing players exposed to industrial prototyping face ongoing cyclicality. Capital allocation flexibility, such as dual listings and buybacks, is increasingly used by European tech firms to broaden investor bases and optimize returns. Industry peers should note the rising importance of segment focus, recurring revenue, and operational agility as key differentiators in a maturing market.